Mehta TH, Goldfarb DS. Uric acid stones and hyperuricosuria. Adv Chronic Kidney Dis. 2012;19(6):413–8.

Article  Google Scholar 

Alvarez-Lario B, Macarron-Vicente J. Uric acid and evolution. Rheumatology (Oxford). 2010;49(11):2010–5.

CAS  Article  Google Scholar 

Moe OW. Uric acid nephrolithiasis: proton titration of an essential molecule? Curr Opin Nephrol Hypertens. 2006;15(4):366–73.

CAS  Article  Google Scholar 

Gaffo AL, Calhoun DA, Rahn EJ, Oparil S, Li P, Dudenbostel T, et al. Effect of serum urate lowering with allopurinol on blood pressure in young adults: a randomized, controlled, crossover trial. Arthritis Rheumatol. 2021;73(8):1514–22.

CAS  Article  Google Scholar 

Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300(8):924–32.

CAS  Article  Google Scholar 

Johnson RJ, Choi HK, Yeo AE, Lipsky PE. Pegloticase treatment significantly decreases blood pressure in patients with chronic gout. Hypertension. 2019;74(1):95–101.

CAS  Article  Google Scholar 

Sleeman I, Lawson RA, Yarnall AJ, Duncan GW, Johnston F, Khoo TK, et al. Urate and homocysteine: predicting motor and cognitive changes in newly diagnosed Parkinson’s disease. J Parkinsons Dis. 2019;9(2):351–9.

CAS  Article  Google Scholar 

Parkinson Study Group S-PDI, Schwarzschild MA, Ascherio A, Casaceli C, Curhan GC, Fitzgerald R, et al. Effect of urate-elevating inosine on early Parkinson disease progression: the SURE-PD3 randomized clinical trial. JAMA. 2021;326(10):926–39.

Article  Google Scholar 

O’Reilly EJ, Liu D, Johns DR, Cudkowicz ME, Paganoni S, Schwarzschild MA, et al. Serum urate at trial entry and ALS progression in EMPOWER. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(1–2):120–5.

CAS  Article  Google Scholar 

Xu LQ, Hu W, Guo QF, Xu GR, Wang N, Zhang QJ. Serum uric acid levels predict mortality risk in male amyotrophic lateral sclerosis patients. Front Neurol. 2021;12:602663.

Article  Google Scholar 

Abate N, Chandalia M, Cabo-Chan AV Jr, Moe OW, Sakhaee K. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int. 2004;65(2):386–92.

CAS  Article  Google Scholar 

Maalouf NM, Cameron MA, Moe OW, Sakhaee K. Metabolic basis for low urine pH in type 2 diabetes. Clin J Am Soc Nephrol. 2010;5(7):1277–81.

CAS  Article  Google Scholar 

Maalouf NM, Poindexter JR, Adams-Huet B, Moe OW, Sakhaee K. Increased production and reduced urinary buffering of acid in uric acid stone formers is ameliorated by pioglitazone. Kidney Int. 2019;95(5):1262–8.

CAS  Article  Google Scholar 

Asplin JR, Goldfarb DS. Effect of thiazolidinedione therapy on the risk of uric acid stones. Kidney Int. 2019;95(5):1022–4.

CAS  Article  Google Scholar 

Bobulescu IA, Park SK, Xu LHR, Blanco F, Poindexter J, Adams-Huet B, et al. Net acid excretion and urinary organic anions in idiopathic uric acid nephrolithiasis. Clin J Am Soc Nephrol. 2019;14(3):411–20.

CAS  Article  Google Scholar 

Kim S, Chang Y, Yun KE, Jung HS, Lee SJ, Shin H, et al. Development of nephrolithiasis in asymptomatic hyperuricemia: a cohort study. Am J Kidney Dis. 2017;70(2):173–81.

Article  Google Scholar 

Narang RK, Gamble GG, Topless R, Cadzow M, Stamp LK, Merriman TR, et al. Assessing the relationship between serum urate and urolithiasis using Mendelian randomization: an analysis of the UK Biobank. Am J Kidney Dis. 2021;78(2):210–8.

CAS  Article  Google Scholar 

Kramer HJ, Choi HK, Atkinson K, Stampfer M, Curhan GC. The association between gout and nephrolithiasis in men: the health professionals’ follow-up study. Kidney Int. 2003;64(3):1022–6.

Article  Google Scholar 

Daudon M, Traxer O, Conort P, Lacour B, Jungers P. Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol. 2006;17(7):2026–33.

CAS  Article  Google Scholar 

Goldfarb DS, MacDonald PA, Hunt B, Gunawardhana L. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors. J Rheumatol. 2011;38(7):1385–9.

CAS  Article  Google Scholar 

Grover PK, Marshall VR, Ryall RL. Dissolved urate salts out calcium oxalate in undiluted human urine in vitro: implications for calcium oxalate stone genesis. Chem Biol. 2003;10(3):271–8.

CAS  Article  Google Scholar 

Ettinger B, Tang A, Citron JT, Livermore B, Williams T. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med. 1986;315(22):1386–9.

CAS  Article  Google Scholar 

Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney Int. 2008;73(4):489–96.

CAS  Article  Google Scholar 

Ferraro PM, Curhan GC. Serum uric acid and risk of kidney stones. Am J Kidney Dis. 2017;70(2):158–9.

Article  Google Scholar 

Kanbara A, Hakoda M, Seyama I. Urine alkalization facilitates uric acid excretion. Nutr J. 2010;9:45.

Article  Google Scholar 

Kenny JE, Goldfarb DS. Update on the pathophysiology and management of uric acid renal stones. Curr Rheumatol Rep. 2010;12(2):125–9.

CAS  Article  Google Scholar 

FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, et al. American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72(6):744–60.

Article  Google Scholar 

Yunhua M, Hao Z, Ke L, Wentao H, Xiaokang L, Jie S. Febuxostat promoted dissolution of radiolucent nephrolithiasis in patients with hyperuricemia. Urol J. 2020;18(1):34–9.

Google Scholar 

Goldberg A, Garcia-Arroyo F, Sasai F, Rodriguez-Iturbe B, Sanchez-Lozada LG, Lanaspa MA, et al. Mini review: reappraisal of uric acid in chronic kidney disease. Am J Nephrol. 2021;52(10–11):837–44.

CAS  Article  Google Scholar 

Su HY, Yang C, Liang D, Liu HF. Research advances in the mechanisms of hyperuricemia-induced renal injury. Biomed Res Int. 2020;2020:5817348.

Google Scholar 

Jung SW, Kim SM, Kim YG, Lee SH, Moon JY. Uric acid and inflammation in kidney disease. Am J Physiol Renal Physiol. 2020;318(6):F1327–40.

CAS  Article  Google Scholar 

Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015;17:90.

Article  Google Scholar 

Bardin T, Nguyen QD, Tran KM, Le NH, Do MD, Richette P, et al. A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout. Kidney Int. 2021;99(1):218–26.

Article  Google Scholar 

Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388–93.

CAS  Article  Google Scholar 

Doria A, Galecki AT, Spino C, Pop-Busui R, Cherney DZ, Lingvay I, et al. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med. 2020;382(26):2493–503.

CAS  Article  Google Scholar 

Badve SV, Pascoe EM, Tiku A, Boudville N, Brown FG, Cass A, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 2020;382(26):2504–13.

CAS  Article  Google Scholar 

Tsukamoto S, Okami N, Yamada T, Azushima K, Yamaji T, Kinguchi S, et al. Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis. Clin Rheumatol. 2021;41(3):911–9.

Article  Google Scholar 

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;(3):1–150.

Timilsina S, Brittan K, O’Dell JR, Brophy M, Davis-Karim A, Henrie AM, et al. Design and rationale for the Veterans Affairs “Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat” trial. Contemp Clin Trials. 2018;68:102–8.

CAS  Article  Google Scholar 

Stamp LK, Farquhar H, Pisaniello HL, Vargas-Santos AB, Fisher M, Mount DB, et al. Management of gout in chronic kidney disease: a G-CAN consensus statement on the research priorities. Nat Rev Rheumatol. 2021;17(10):633–41.

Article  Google Scholar 

White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200–10.

CAS  Article  Google Scholar 

Keenan RT, Botson JK, Masri KR, Padnick-Silver L, LaMoreaux B, Albert JA, et al. The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review. Semin Arthritis Rheum. 2021;51(2):347–52.

CAS  Article  Google Scholar 

O’Dell JR, Brophy MT, Pillinger MH, Neogi T, Palevsky PM, Wu H, et al. Comparative effectiveness of allopurinol and febuxostat in gout management. NEJM Evid 2022;1(3). https://doi.org/10.1056/EVIDoa2100028

Khanna P, Johnson RJ, Marder B, LaMoreaux B, Kumar A. Systemic urate deposition: an unrecognized complication of gout? J Clin Med. 2020;9(10):3204.